Antigenics (ATGC) Price & Analysis

Q: What was Antigenics’s price range in the past 12 months?

Antigenics lowest stock price was <$0.01 and its highest was $0.01 in the past 12 months.

Q: What is Antigenics’s market cap?

Antigenics’s market cap is $92.00.

Q: When is Antigenics’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

Q: Is Antigenics overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Q: Does Antigenics pay dividends?

Antigenics does not currently pay dividends.

Q: What is Antigenics’s EPS estimate?

Antigenics’s EPS estimate for its next earnings report is not yet available.

Q: How many shares outstanding does Antigenics have?

Antigenics has 45,844,000 shares outstanding.

Q: Which hedge fund is a major shareholder of Antigenics?

Currently, no hedge funds are holding shares in ATGC

Q: What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

11 Followers

ATGC Stock Chart & Stats

$0.01

<$0.01(100.00%)

At close: May 14 4:00 PM EDT

$0.01

<$0.01(100.00%)

Day’s Range― - ―

52-Week Range<$0.01 - $0.01

Previous CloseN/A

VolumeN/A

Average Volume (3M)10.75K

Market Cap

$92.00

Enterprise ValueN/A

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

Beta-25.09

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding45,844,000

10 Day Avg. Volume10,750

30 Day Avg. Volume10,750

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.00

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

ATGC FAQ

What was Antigenics’s price range in the past 12 months?

Antigenics lowest stock price was <$0.01 and its highest was $0.01 in the past 12 months.

What is Antigenics’s market cap?

Antigenics’s market cap is $92.00.

When is Antigenics’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Antigenics’s earnings last quarter?

Currently, no data Available

Is Antigenics overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Antigenics pay dividends?

Antigenics does not currently pay dividends.

What is Antigenics’s EPS estimate?

Antigenics’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Antigenics have?

Antigenics has 45,844,000 shares outstanding.

What happened to Antigenics’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Antigenics?

Currently, no hedge funds are holding shares in ATGC

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Antigenics

Antigenics, Inc., a clinical-stage biopharmaceutical company, discovers, manufactures, and develops immunotherapies for cancer. The company was founded in 1994 and is based in Lexington, Massachusetts.